Real-World Effectiveness of Letermovir Prophylaxis after Allogeneic Hematopoietic Cell Transplantation in a Middle-Income Country Setting (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #784; 591; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "Letermovir prophylaxis was associated with a marked reduction and delay in CMV reactivation and the absence of refractory/resistant CMV infection. These findings extend current evidence to a middle-income country, underscoring the need for equitable access to CMV prevention strategies in resource-limited settings. 1 ."
Clinical • Real-world • Real-world effectiveness • Real-world evidence • Chronic Kidney Disease • Cytomegalovirus Infection • Infectious Disease • Nephrology • Renal Disease • Transplantation
|
|
Jayr Schmidt-Filho, M.D 1,2; Luciana Garcia di Paolo, M.D 1,2; Anita Cassoli Cortez, M.D 1,2; Bianca Batista Cal, M.D 1,2; Julia Aith Balthazar, M.D 1,2; Ana C Cordeiro, M.D 1,2; Vanessa A Bovolenta, M.D 1,2; Marjorie Vieira Batista, M.D, TID, Ph.D 1,3
|